A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
A phase 1/2 trial of Ifinatamab deruxtecan, Atezolizumab, Carboplatin in small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) is a phase 1/2 interventional study registered as NCT07227597 by Merck Sharp & Dohme LLC, with 170 participants planned, started 2026-01-29 and due to reach its primary completion in 2030-11-29. Interventions recorded: Gocatamig, I-DXd, Atezolizumab, Carboplatin, Etoposide. Conditions listed: Small Cell Lung Cancer Extensive Stage. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialPembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
Shares Etoposide, Atezolizumab, Merck & Co. (MSD), Carboplatin.
- TrialA Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-
Shares Ifinatamab deruxtecan, Atezolizumab, Carboplatin, Small-cell lung cancer.
- TrialA Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
Shares Ifinatamab deruxtecan, Atezolizumab, Small-cell lung cancer.
- TrialDAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment
Shares Etoposide, Atezolizumab, Carboplatin, Small-cell lung cancer.
- TrialSafety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Shares Etoposide, Atezolizumab, Carboplatin, Small-cell lung cancer.
- TrialA Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensiv
Shares Ifinatamab deruxtecan, Merck & Co. (MSD), Small-cell lung cancer.
- TrialBL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
Shares Etoposide, Atezolizumab, Carboplatin, Small-cell lung cancer.
- TrialStudy of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
Shares Etoposide, Atezolizumab, Carboplatin, Small-cell lung cancer.